Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy

Record History

See every version on ClinicalTrials.gov ↗

1. Minor Sep 22, 2026 Trial completed Show 6 more changesShow less

   • Final enrollment: 84 participants (planned 100)
   • Study completion date changed from estimate of Sep 1, 2029 to Sep 22, 2026
   • Eligibility criteria expanded, about 10 words
   • Secondary endpoints: details revised at 3 of 12 entries
   • Site details revised at 2 of 2 sites
   • Publications: details revised at 1 of 1 entry
2. Minor Apr 28, 2026 Primary completion date: Dec 20, 2026 to Sep 1, 2026

   • Study completion date: Dec 20, 2028 to Sep 1, 2029

   v6
3. Feb 28, 2025 Re-verified, no change to tracked fieldsv5
4. Notable Feb 24, 2025 Lead sponsor: Frede Donskov to Niels Fristrupv4 Show 4 more changesShow less

   • Primary completion date: Dec 20, 2021 to Dec 20, 2026
   • Study sites: 3 to 2
   • Study completion date: Dec 20, 2022 to Dec 20, 2028
   • Study description revised
5. Notable Apr 22, 2020 Primary completion date: Dec 20, 2019 to Dec 20, 2021

   • Study completion date: Dec 20, 2020 to Dec 20, 2022

   v3
6. Minor Aug 30, 2019 Site contacts updated at 1 of 3 sitesv2
7. Jul 9, 2018 Study First Submitted

• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.